A fully liquid vaccine, it reportedly protects infants against six WHO priority diseases, including polio
Sanofi Pasteur, the vaccines global business unit of Sanofi, has announced the launch of its ready-to-use fully liquid 6-in-1 vaccine – Hexaxim. The vaccine, indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age, provides protection against six major childhood diseases – diphtheria, tetanus, pertussis (whooping cough), polio, Haemophilus influenza B and hepatitis B.
The burden of the six diseases is significant, particularly in infants. Consequently, the WHO and the wide majority of countries around the world recommend vaccination against these diseases. India, under the Universal Immunization Program, also offers protection against these six major diseases.
Globally, Hexaxim is a combination vaccine with acellular pertussis (acP) and inactivated poliovirus vaccine (IPV) which has received a prequalification by the WHO.
Sharing his comments on the launch, Jean-Pierre Baylet, Country Head – Sanofi Pasteur India, Nepal and Sri Lanka said, “Hexaxim brings to life Sanofi Pasteur’s mission to improve human health by developing superior innovative vaccination solutions against infectious diseases. Given the large influx of patients met by pediatricians in India, Hexaxim will offer convenience and ensure consistency in administering the right dose of each antigen every single time.”
Hexaxim, during its clinical study assessment, was found to be safe and well tolerated as a primary series and booster vaccination in all schedules, countries, and ethnicities tested.